A Beat-and-Raise the Tape Sold Again: 2026’s Re-Acceleration Is Half-Funded by an IPR&D Definition Change — Maintaining Hold, One Clean Quarter From an Upgrade

Results vs. Consensus

Q4 2025 Scorecard

Year-Over-Year Comparison (Q4)

The Q4 adjusted-EPS line (+25.5% YoY) is itself slightly flattered by a smaller IPR&D charge than a year ago, but the direction is unambiguous and the revenue and segment lines tell the real story: immunology and neuroscience both compounded in the mid-to-high teens, while oncology and aesthetics remained the two laggards — the same shape as every quarter of 2025.

Sequential (QoQ) Context

The +45.7% sequential adjusted-EPS jump is pure IPR&D noise — Q3 carried a $1.50 charge, Q4 carried only $0.71 — not an operational step-change. On the clean ex-IPR&D basis the two quarters earned ~$3.36 and ~$3.42, up modestly, exactly what a business growing revenue 5.3% sequentially with stable margins should produce. The aesthetics sequential bounce (~+9%) is largely seasonal (Q4 is a stronger aesthetics quarter); the trend number to watch is the FY YoY (−6.1%), not the QoQ.

Full-Year 2025 Summary

The full-year scorecard is the cleanest way to see the franchise. Revenue hit a record $61.160B, more than $2B above the initial February guide and a new all-time high — despite nearly $16B of cumulative U.S. Humira erosion since its loss of exclusivity. The headline FY2025 adjusted EPS of $10.00 declined 1.2%, but that figure carries a $2.76/share full-year IPR&D charge; on a like-for-like ex-IPR&D basis the year earned ~$12.76 and grew. This $10.00 / ~$12.76 distinction is the single most important number in the release, because the 2026 guide is set on the ex-IPR&D definition — the basis flip is the analytical center of gravity for the whole report.

Quality of Beat

Revenue: The ~$0.26B Q4 overachievement was concentrated where the thesis wants it — Skyrizi and Rinvoq in immunology, and a broad-based neuroscience beat — not in one-time items or channel stocking. Reported growth of 10.0% versus operational growth of 9.5% means FX was a modest favorable tailwind; this was an organic-demand beat. The off-scorecard number that matters most is the ex-Humira platform up +14.5% reported, the engine that lets AbbVie grow comfortably through the still-large legacy decline.

Margins: The reported adjusted operating margin of 38.3% looks soft against the high-40s the franchise prints at scale, but it carries a 7.6-point unfavorable hit from acquired IPR&D this quarter. Strip it and the underlying operating margin is back in the mid-40s, consistent with AbbVie at scale; the CFO guided 2026 adjusted operating margin to ~48.5%, meaningful expansion. Adjusted gross margin of 83.6% was in line and guided above 84% for 2026. The mix continues to quietly improve: the two highest-margin franchises (immunology, neuroscience) are growing fastest while the lowest-incremental-margin one (aesthetics) shrinks.

EPS: The $0.05 beat is fully operational — the $0.71 IPR&D charge and its lower tax deductibility (which lifted the Q4 adjusted tax rate to 18.3%) sit inside both the print and the consensus bar, so they net out of the beat/miss. Below the line, net interest expense of $655M and a roughly flat share count were as modeled. The cleaner read is the ex-IPR&D ~$3.42, which beat the top of management’s own guide — the operational earnings power is comfortably ahead of where the $10.00 FY headline suggests once the BD bill is set aside.

Segment Performance

Therapeutic-Area Revenue Mix — Q4 2025

Immunology — The Engine Compounds Through the Humira Tail

Immunology delivered total Q4 revenues of approximately $8.6B, with the composition again the story. Skyrizi grew 31.9% operationally to $5.0B and Rinvoq grew 28.6% operationally to nearly $2.4B — a combined ~$7.4B still compounding ~30% — while Humira fell 26.1% operationally to just over $1.2B. On a full-year basis the immunology portfolio reached $30.406B (+14.0%), with Skyrizi at $17.562B, Rinvoq at $8.304B, and Humira at $4.540B. The crossover is decisive and largely behind the company: Skyrizi and Rinvoq have together exceeded peak Humira sales by more than $4.5B, and management framed them as “on pace to deliver more than 20% growth in 2026” in their eighth year on the market. Capture-rate detail was unusually granular: Skyrizi holds ~75% of frontline in-play IBD patients (~80% in Crohn’s), and the Tremfya entry has not dented new-patient starts.

“SKYRIZI and RINVOQ are a great pair in IBD. SKYRIZI is well-positioned in frontline, and we see more opportunity than ever before for RINVOQ in the second line plus setting. So together, our two brands have already exceeded peak HUMIRA sales by more than $4.5 billion and are on pace to deliver more than 20% growth in 2026.” — Jeffrey Stewart, Chief Commercial Officer

Assessment: This is the load-bearing wall of the thesis and it is intact and, if anything, de-risked further. The 2026 immunology guide of $34.5B (Skyrizi $21.5B, Rinvoq $10.1B, Humira $2.9B) embeds another year of ~30% combined Skyrizi/Rinvoq growth and a Humira tail that is now small enough (guided to $2.9B for the full year) that even continued erosion is a manageable absolute drag. The only debate left on this franchise is the multiple you pay for it, not the trajectory.

Neuroscience — The Second Engine Keeps Compounding

Neuroscience grew 17.3% operationally in Q4 to more than $2.9B, capping a full year of $10.767B (+19.6%) — the fastest-growing therapeutic area and now AbbVie’s clear second pillar. The drivers were broad: Vraylar at $1.0B in the quarter, Botox Therapeutic at $990M, Ubrelvy at $339M, and Qulipta at $288M. The standout remains Parkinson’s: Vyalev grew ~33% sequentially to $183M, with management calling international uptake “exceptionally strong” and pointing to a fresh U.S. coverage inflection. On the full year, combined Ubrelvy + Qulipta reached $2.307B and Botox Therapeutic $3.769B.

“Violet’s launch continues to be outstanding. Total sales were $183 million in the quarter, up approximately 33% on a sequential basis... Given these insights and the robust early launch trends globally, we now expect Violet to achieve blockbuster revenue in 2026.” — Jeffrey Stewart, Chief Commercial Officer

Management again argued the Street under-weights neuroscience, sizing the Parkinson’s franchise (Vyalev + tavapadon + Duopa) at >$5B peak and the migraine franchise (Ubrelvy + Qulipta) at >$5B peak — both above prior long-term guidance — alongside a deep psychiatry pipeline (932, bretisilocin, emraclidine) to replace Vraylar at its ~2030 LOE.

Assessment: Neuroscience remains the most underappreciated part of the story and a genuine second pillar. The 2026 guide of $12.5B (Vraylar $4.0B, Botox Therapeutic $4.1B, oral CGRP $2.9B, Vyalev $1.0B) implies continued mid-teens growth and would, on management’s telling, put AbbVie at #1 in neuroscience industry-wide. The Vyalev/tavapadon Parkinson’s leg is the cleanest piece of un-modeled optionality in the portfolio — and the flat-to-down stock reaction again did not reward it.

Oncology — Still the Drag, and 2026 Is Guided Down

Oncology declined 2.5% operationally in Q4 to ~$1.7B — a step back from the roughly-flat Q3 — as Imbruvica fell 20.8% operationally on continued CLL competition. Venclexta ($710M, +6.4% op.) remains the bright spot, with all-oral fixed-duration combination use building in CLL, and Elahere, Epkinly, and Emrelis all growing double-digits. On the full year, oncology reached $6.655B (+1.5%), with Imbruvica at $2.869B, Venclexta at $2.792B, and Elahere at $690M. The R&D narrative is more compelling than the revenue line: the Temab-A ADC is advancing to a Phase III all-comers colorectal study, and the new Remagen PD-1×VEGF bispecific will combine with it across solid tumors.

“Double-digit sales growth from Elahere, Epkinly, and Emrelis also helped to partially offset the expected sales decline for IMBRUVICA, which was down 20.8%... And we do anticipate IMBRUVICA IRA pricing will unfavorably impact our oncology portfolio growth in 2026.” — Jeffrey Stewart, Chief Commercial Officer

Assessment: Oncology is the one franchise where 2026 is guided down — management set the 2026 number at $6.5B, with Imbruvica falling to ~$2.2B as IRA pricing compounds the competitive erosion (Venclexta $3.0B and Elahere $850M partly offset). This is a real near-term drag on the consolidated growth rate, and it is one of the specific reasons the stock could not rally on an otherwise strong print. Net: a near-term negative on the model, an option on the back half of the decade via the ADC/bispecific pipeline.

Aesthetics — Q4 Narrows the Decline, but the Full Year Confirms the Weakness

Aesthetics fell just 1.2% operationally in Q4 to ~$1.3B — a notably narrower decline than earlier in the year — with Botox Cosmetic actually growing 3.8% operationally to $717M while Juvederm fell 10.8% to $249M. But the full-year picture is the one that matters for the thesis: aesthetics declined 6.1% reported to $4.860B, with Botox Cosmetic at $2.602B and Juvederm at $993M. Management again framed the category, not AbbVie’s position, as the problem — “economic headwinds have continued to impact market conditions globally” — and pointed to the “Only You” Botox campaign, injector-training expansion, and the 2026 Trenibot E launch as the catalysts to re-stimulate a still-underpenetrated market.

“We’ve seen over the last several quarters, economic headwinds have continued to impact market conditions globally, and we anticipate category growth will remain challenged in 2026.” — Jeffrey Stewart, Chief Commercial Officer

The 2026 aesthetics guide is ~$5.0B (Botox Cosmetic $2.7B, Juvederm $950M) — roughly flat versus the $4.860B 2025 base, i.e., management is calling a stabilization but explicitly not a recovery. The toxin-vs-filler split is informative: toxins (Botox Cosmetic +3.8% op. in Q4) are holding, while fillers (Juvederm −10.8%) remain in a deeper, possibly structural, “natural look”-driven decline.

Assessment: The Q4 toxin growth is the first genuinely green shoot in this franchise in over a year, and the narrowing operational decline supports the “approaching a trough” case. But the full year was down 6.1% and the 2026 guide is flat, not up — so this is still “stabilizing, not recovered.” The honest read carries forward from Q3: aesthetics has moved from a clear drag toward a stabilizing line, which is supportive, but a guide that says ~flat-at-$5.0B is not yet the “confirmed aesthetics trough” that is one of our explicit upgrade triggers. Closer than at Q3 — but not there.

Key Topics & Management Commentary

Overall Management Tone: Confident and forward-leaning, with the posture of a management team that believes it has under-promised and is now delivering the long-deferred long-term raise inside the 2026 guide. The call spent most of its airtime on the durability of Skyrizi/Rinvoq and the breadth of the neuroscience and oncology pipelines, treating the FY2025 beat as routine. Management was least convincing on aesthetics — conceding category weakness will persist into 2026 — and notably did not foreground the IPR&D definition change that drives most of the optical 2026 EPS jump, leaving the Street to do that reconciliation itself.

1. The 2026 Guide and the IPR&D Definition Change

The defining disclosure of the call is the 2026 adjusted-EPS guide of $14.37–$14.57 (mid $14.47) — and the policy change underneath it. Where 2025 ran acquired IPR&D through adjusted EPS (the convention that depressed FY2025 to $10.00 via a $2.76 charge), the 2026 guide excludes any future acquired-IPR&D impact entirely. The CFO stated the exclusion plainly but did not dwell on how much of the optical $10.00 → $14.47 jump it accounts for.

“Our full-year adjusted earnings per share guidance is between $14.37 and $14.57. Please note that this guidance does not include an estimate for acquired IPR&D expense that may be incurred throughout the year.” — Scott Reents, Chief Financial Officer

The arithmetic matters. FY2025 adjusted EPS on the same ex-IPR&D basis as the 2026 guide was ~$12.76 ($10.00 + $2.76). So the clean, like-for-like 2026 growth is ~$14.47 / ~$12.76 ≈ +13.4% — a real and impressive re-acceleration, but materially below the +44.7% the raw $14.47-vs-$10.00 headline implies. Against the ~$14.19 Street consensus, the guide is an optical ~+2% beat, but harmonizing the bases makes that beat softer than it first appears.

Assessment: This is the analytical centerpiece of the print, and getting it right is the difference between “AbbVie just guided to +45% EPS growth” and “AbbVie guided to ~+13% clean growth and changed how it counts.” It is the latter, and the ~+13% is genuinely good. But a 2026 number built partly on an accounting reset is exactly the kind of “beat that requires an asterisk” that a quality compounder priced for execution struggles to rally on. We want the first clean 2026 print to confirm the ~$14.47 is durable earnings power — that is the central reason we hold the rating one more quarter rather than upgrading now.

2. The Long-Term Skyrizi/Rinvoq Raise — Finally Delivered, Inside the Guide

For two straight quarters management deferred a formal refresh of its long-term Skyrizi/Rinvoq targets to “the Q4 call.” That refresh effectively arrived: the 2026 guide puts combined Skyrizi + Rinvoq sales above $31B, which the CEO noted is already $0.5B above the 2027 long-term target — a year early — with both assets expected to grow robustly into the 2030s.

“The main drivers of this growth include SKYRIZI and RINVOQ, with combined sales of more than $31 billion, already surpassing our 2027 long-term guidance by half a billion... we are well-positioned to deliver high single-digit revenue growth through 2029.” — Robert Michael, Chairman & CEO

Pressed directly on whether the Street now fully models the two assets, the CEO argued there is still upside not in consensus — longer-term Skyrizi/Rinvoq growth into the 2030s, plus under-modeled neuroscience ($5B+ Parkinson’s and $5B+ migraine franchises) and an oncology pipeline (Temab-A in CRC) the Street barely credits.

Assessment: This is a genuine positive and a partial check of one of our three upgrade triggers — the long-deferred long-term franchise raise. Surpassing the 2027 combined target a full year early, embedded in a hard guide rather than a hand-wave, is the most concrete validation yet that the growth platform is conservatively modeled. We treat it as a meaningful tilt toward an upgrade, but not the standalone trigger, because management delivered it bundled with the IPR&D basis change and a soft Q1 — so the market read it as “in the price” rather than as fresh fuel. The trigger is largely satisfied; we want it confirmed by a clean first-quarter print on the new basis.

3. The Through-2029 Growth Commitment

Beyond the one-year guide, management made an explicit multi-year commitment: “high single-digit revenue growth through 2029,” with no significant LOEs until the next decade. The 2026 revenue guide of ~$67B (+9.5%) sits at the top of that range, and the CEO framed the diversity of the portfolio — five growth areas spanning immunology, neuroscience, oncology, aesthetics, and a nascent obesity option — as the reason the durability extends well past the current indication set.

“Given the strong outlook of our diverse portfolio, we are well-positioned to deliver high single-digit revenue growth through 2029... with no significant LOEs until the next decade, we have plenty of capacity to invest.” — Robert Michael, Chairman & CEO

Assessment: A high-single-digit top-line CAGR through 2029, layered with operating leverage (2026 operating margin guided to ~48.5% from the mid-40s underlying 2025), is the mechanical case for AbbVie compounding EPS at low-double-digits through the decade. This is the durability pillar of the bull case, and it strengthened. The caveat is that it is a revenue commitment; the EPS translation depends on the IPR&D cadence the new guide definitionally excludes.

4. Humira: The Cliff Is Now a Small, Fading Tail

Humira delivered Q4 global sales of more than $1.2B, down 26.1% operationally, and FY2025 sales of $4.540B — with management guiding 2026 Humira to just $2.9B as more plans move to exclusive biosimilar contracts. The CEO framed the full-year story as growing to a record despite nearly $16B of cumulative U.S. Humira erosion since the LOE.

“Our sales growth of 8.6% led to a new all-time high for AbbVie, exceeding our previous peak revenue by more than $3 billion, despite nearly $16 billion of US HUMIRA erosion since the LOE.” — Robert Michael, Chairman & CEO

Assessment: The five-year cliff narrative that defined the bear case is effectively closed. Humira at a guided $2.9B in 2026 is <5% of revenue and shrinking; the absolute step-down is now small enough that the growth platform earns through it without strain. This is the bull pillar that has moved from “thesis question” to “settled fact” over the course of 2025 — confirmed and now largely de-risked.

5. Aesthetics: A Toxin Green Shoot Inside a Flat 2026 Guide

Aesthetics is the franchise where management was least able to point to growth. The Q4 toxin line was a genuine positive — Botox Cosmetic +3.8% operationally — but fillers (Juvederm −10.8%) remain weak, the full year was down 6.1%, and the 2026 guide is ~flat at ~$5.0B. Management leaned on market-stimulation programs (the “Only You” Botox campaign, unbranded filler education, three new U.S. AMI training centers) and the 2026 Trenibot E short-duration toxin launch as the levers.

“With our leading market shares relatively stable for both toxins and fillers, we are focused on investing to stimulate the market, which remains highly underpenetrated... we anticipate category growth will remain challenged in 2026.” — Jeffrey Stewart, Chief Commercial Officer

Assessment: Two signals point in opposite directions, as at Q3: the Q4 operational decline narrowed to −1.2% and toxins returned to growth (the trough-forming pattern), but the full year was −6.1% and 2026 is guided flat, not up. The honest read is “stabilizing, getting closer to a trough, but not yet confirmed.” This is the second of our three upgrade triggers, and it is closer than it was at Q3 — but a flat guide is not a recovery, and fillers are still structurally soft.

6. Capital Allocation: Free Cash Flow, the Dividend, and a Growing Royalty Drag

The CFO guided 2026 free cash flow to $18.5B — but flagged that this figure now includes roughly $3.5B of Skyrizi royalty payments, a rising obligation. Management reiterated the “strong and growing” dividend (up more than 330% since the 2013 inception) and a continued BD cadence funded out of cash flow. The 2026 P&L guide also embedded a step-down in the non-GAAP tax rate to ~14% (from 18% in 2025, which had carried a 3-point IPR&D drag) on recent tax-law changes, and ~$2.8B of net interest expense including anticipated refinancing.

“We expect to generate free cash flow of $18.5 billion in 2026, which includes roughly $3.5 billion of SKYRIZI royalty payments. This free cash flow will support a strong and growing quarterly dividend, which we have increased by more than 330% since inception.” — Scott Reents, Chief Financial Officer

Assessment: The capital-allocation posture is unchanged and sound — ~$18.5B of free cash flow comfortably funds the dividend and the BD machine without dilution or over-leverage. The one watch item is the disclosed $3.5B Skyrizi royalty drag inside that number; it is a reminder that a meaningful slice of Skyrizi economics is shared, and it caps how much of the franchise’s growth converts to AbbVie free cash flow. The ~14% 2026 tax rate is a tailwind worth noting in the EPS bridge.

7. The Voluntary U.S. Government Pricing Agreement

Management disclosed a three-year voluntary agreement with the U.S. government that, in management’s telling, balances affordability with the ability to invest in innovation: low Medicaid prices, expanded direct-to-patient cash-pay options for select products, and a $100B U.S. R&D and capital-investment commitment over the next decade. Crucially, management said the agreement exempts AbbVie, during its term, from tariffs and from pricing mandates including demonstration projects.

“Key elements of this three-year agreement include offering low prices in Medicaid, expanding direct-to-patient cash pay options for select products, and committing $100 billion in US R&D and capital investments over the next decade.” — Robert Michael, Chairman & CEO

Assessment: This materially de-risks one of the bear pillars — the tariff/pricing-mandate overhang that hung over the 2026–27 setup. A term-length exemption from tariffs and demonstration projects, in exchange for a $100B investment commitment AbbVie was largely going to make anyway, is a favorable trade. It does not remove IRA exposure (Imbruvica pricing still hits 2026 oncology, and Botox was selected for 2028 Medicare negotiation), but it converts the broad policy overhang from “unquantified tail risk” toward “managed and bounded.”

8. Business Development: $5B+ Invested in 2025, Building the 2030s

Management invested more than $5B in new business development in 2025 (30+ deals over the last two years, >$8B), spanning an in vivo CAR-T platform (Capstan), a next-gen psychedelic for depression (bretisilocin), a trispecific for multiple myeloma (ISB 2001), an amylin analog for obesity (ABBV 295), a siRNA platform (8Rx), and the Remagen PD-1×VEGF bispecific. The CEO was explicit that AbbVie is willing to do late-stage deals, not just early-stage ones, but has no need given a de-risked decade.

“Given our strong growth outlook and no LOEs this decade, we have plenty of firepower to pursue both early and late-stage opportunities. We’re not limited to early stage, and we’re focused on our core areas — immunology, neuroscience, oncology, and building out obesity.” — Robert Michael, Chairman & CEO

Assessment: The BD machine remains a genuine differentiator — pipeline optionality funded out of cash flow rather than dilution or leverage. The cost is the recurring, lumpy IPR&D drag that distorted every 2025 adjusted print — and which the 2026 guide now simply excludes. That exclusion is a double-edged sword: it cleans up the headline, but it also means the 2026 EPS guide systematically understates the BD spend that will actually occur, so reported 2026 EPS will likely land below the $14.47 mid once real IPR&D charges are booked. Investors should model the guide as an ex-IPR&D number, not an all-in one.

9. Pipeline Catalysts: A Dense 24-Month Slate

R&D leadership flagged a deep near-term catalyst slate: pivotal data for three additional Rinvoq indications plus the Skyrizi/Rinvoq Crohn’s combination platform in immunology; neuroscience readouts for 932 (bipolar), bretisilocin (MDD), and emraclidine (schizophrenia); registrational etentamig data and Temab-A solid-tumor readouts in oncology; and early obesity (amylin) data later this year. Rinvoq’s “next wave” dermatology indications (vitiligo, alopecia areata, HS) were sized at $2B+ in combined peak sales.

“We anticipate a number of key catalysts across our core therapeutic areas over the next 24 months... These are all very exciting opportunities that have the potential to drive sustained long-term growth.” — Robert Michael, Chairman & CEO

Assessment: These extend the immunology, neuroscience, and oncology runways into the late 2020s and reinforce that the franchise has multi-year duration beyond the current indication set. Positive for the long-term thesis, but largely 2027–2029 contributors — they support the durability case without changing the near-term setup that drives a Hold today.

Guidance & Outlook

The bridge that explains the muted reaction: The 2026 adjusted-EPS guide of $14.37–$14.57 looks like a ~+45% leap from $10.00, but that comparison straddles two different definitions. FY2025’s $10.00 ran $2.76 of IPR&D through the adjusted line; the 2026 guide excludes IPR&D entirely. Put both on the same ex-IPR&D basis — FY2025 ~$12.76 vs. 2026 ~$14.47 — and the clean growth is ~+13.4%. That is genuine, high-quality re-acceleration driven by the Skyrizi/Rinvoq engine, operating leverage (margin to ~48.5%), and a lower tax rate (~14%). But it is roughly a third of what the raw headline implies, and the optical ~+2% beat of the ~$14.19 Street consensus shrinks once the bases are harmonized. The reported 2026 number will also land below $14.47 to the extent AbbVie books real IPR&D during the year — the guide is, by design, a ceiling that future deals will reduce.

The soft Q1 set-up: The initial Q1 2026 guide of $2.97–$3.01 adjusted EPS on ~$14.7B revenue sits below the ~$3.12 the Street carried for the quarter. Management attributed the softness to typical seasonality plus an unfavorable RINVOQ price comparison tied to the timing of prior-year rebates in the first half — a high-single-digit price headwind for Rinvoq specifically in Q1. The CFO was explicit that 2025 had pricing tailwinds in the first half that reverse as comparisons, so Q1 is the trough quarter of the year. The mechanics are benign, but a first guide below the Street on the very next quarter is precisely the kind of near-term blemish that prevents a beat-and-guide from being read as clean.

Implied shape: A ~$14.7B Q1 ramping to ~$67B for the year implies an average ~$17.4B in Q2–Q4, i.e., the back half does the heavy lifting — consistent with Skyrizi/Rinvoq compounding, the Humira step-down concentrated early, and the Rinvoq rebate comparison easing after the first half. The 2026 operating-margin guide of ~48.5% (from a mid-40s underlying 2025) is the EPS-leverage story on top of the revenue growth.

Street at: Pre-print, the Street carried ~$14.19 FY2026 adjusted EPS and ~$3.12 for Q1. The guide midpoint ($14.47) sits ~2% above the FY Street on its face; the Q1 guide ($2.97–$3.01) sits below the Q1 Street. The net read — an above-consensus full year built partly on a definition change, with a below-consensus next quarter — is why the “beat” did not feel like one to the tape.

Guidance style: Characteristically conservative on revenue (the +9.5% guide top-ticks the through-2029 high-single-digit commitment) and deliberately clean on EPS (excluding the IPR&D the company knows it will spend). AbbVie has earned the benefit of the doubt on the revenue line — it beat its initial 2025 guide by more than $2B — but the EPS-basis change means the 2026 headline should be read as an ex-IPR&D ceiling, not an all-in expectation.

Analyst Q&A Highlights

Whether the Street Now Fully Models Skyrizi and Rinvoq

The dominant line of questioning on the call probed whether, with the long-term targets now effectively surpassed a year early, there is any upside left to model in the two flagship immunology assets. Management argued there is — pointing to growth into the 2030s not yet in consensus and, more emphatically, to under-modeled neuroscience and oncology beyond the two drugs.

Q: “I’ve been reading more investors feeling that the Street now better understands the potential for SKYRIZI and RINVOQ over time... Is the market now largely getting this right at this point? Or do you see further potential for growth upside?”
— Christopher Schott, JPMorgan

A: “The combined guidance for this year is already $500 million higher than our 2027 estimate, and we do expect both SKYRIZI and RINVOQ to grow robustly into the 2030s. And clearly, as we look at models, that longer-term growth is not reflected... beyond immunology, what’s underappreciated is both neuroscience and oncology in particular.”
— Robert Michael, Chairman & CEO

Assessment: A confident answer that did the work of a long-term guide raise — surpassing the 2027 combined target a year early, in a hard guide. The pivot to neuroscience and oncology being “underappreciated” is the tell: management believes the next leg of credit the Street owes it is in the second and third franchises, not another immunology bump. Thesis-positive, and the clearest articulation yet that the platform is conservatively modeled.

Appetite and Risk Profile for Larger Business Development

A recurring line of questioning sought to size AbbVie’s BD appetite going forward — specifically whether the early/mid-stage focus precludes larger, later-stage deals. Management reframed: it has the wherewithal and the willingness for late-stage transactions, but no need, given a decade with no major LOE.

Q: “Maybe you could give us an update on your BD lens, kind of the size and risk profile of potential deals you might consider... how are you thinking about the opportunities on the forward here?”
— Terence Flynn, Morgan Stanley

A: “Given our strong growth outlook and no LOEs this decade, we have plenty of firepower to pursue both early and late-stage opportunities. We’re not limited to early stage... to the extent we see a differentiated asset in any of our core areas, whether early or late stage” we’ll pursue it.
— Robert Michael, Chairman & CEO

Assessment: Reassuring for capital-allocation risk. The “late-stage deal is not a need” framing argues against a value-destroying mega-merger to plug a hole that does not exist — the most common way a cash-rich pharma destroys value. The flip side, made explicit by the 2026 guide’s IPR&D exclusion, is that the recurring IPR&D drag is now a structural, permanently-excluded feature of every print.

Aesthetics: Quantifying the Trenibot E Opportunity

Questioning pressed for quantitative framing on the aesthetics revitalization — specifically the commercial opportunity from the 2026 Trenibot E (short-duration toxin) launch, given investor debate about whether it can move the needle on a franchise in a protracted downturn. Management declined a hard number but laid out the mechanism: a near-doubling of the patient inflow funnel at peak, and a higher conversion rate to full-strength Botox.

Q: “[Aesthetics has] been in a protracted downturn based on macro headwinds... Are you able to provide any quantitative framing on what you expect to see post-approval and launch [of Trenibot E]... recognizing that there’s some investor debate about the commercial opportunity?”
— Asad Haider, Goldman Sachs

A: “At peak, we could potentially up to double the inflow of patients that would basically start to move into the toxin market... it’s really gonna not really appear until towards the end of the year, but it’s gonna gate heavily into ’27... we have a much higher conversion rate than our existing share. So it starts to build share as well.”
— Jeffrey Stewart, Chief Commercial Officer

Assessment: A candid “the mechanism is real but the timing is 2027” answer — which is exactly why aesthetics stays a Hold-capping line rather than an upgrade catalyst for 2026. Doubling the funnel and lifting conversion is a credible long-term lever, but management explicitly placed the revenue impact in 2027 and beyond, with 2026 guided flat. The trough-forming evidence (Q4 toxin growth) is encouraging; the recovery is still a year out on management’s own telling.

The Botox Medicare Negotiation Selection and Cosmetic Pricing Spillover

A pointed exchange probed the surprise selection of Botox for 2028 Medicare price negotiation, and whether a therapeutic-side price cut would bleed into the cosmetic franchise given historically linked pricing. Management expressed disappointment at the selection (arguing a plasma-derived product should have been excluded) but said it had planned conservatively for it and saw limited cosmetic spillover.

Q: “We were sort of surprised to see [Botox] selected for the Medicare price reductions in 2028... what that might mean for pricing on the cosmetic side? Because I think it’s always been tied to therapeutic and cosmetic pricing.”
— Vamil Divan, Guggenheim Securities

A: “We did plan conservatively that it could be selected based on CMS spend, so its selection does not impact our long-term growth guidance at all... we don’t see a large or meaningful interaction between the two even if we do see the negotiation take place in ’28.”
— Robert Michael, Chairman & CEO / Jeffrey Stewart, Chief Commercial Officer

Assessment: Adequately handled and not a near-term P&L issue — effective 2028, planned for, with a credible argument (the cash-pay nature of cosmetic Botox) that the therapeutic cut does not mechanically flow to the cosmetic line. It is one more data point that the IRA/policy overhang is bounded rather than open-ended, but it does keep a 2028 question mark on the highest-margin aesthetics asset.

SKYRIZI in IBD: Durability Against the Tremfya Entrant

Questioning sought to test the durability of Skyrizi’s IBD leadership now that an in-class IL-23 competitor has launched — specifically whether new-start share has held in both Crohn’s and ulcerative colitis. Management argued new-patient starts are stable and high, with frontline capture rates that signal clear physician preference.

Q: “It sounds like you haven’t really seen any change in new start share here with the Tremfya entry. Is that the case in both Crohn’s and UC, or is that just more a holistic kind of IBD comment?”
— Christopher Schott, JPMorgan

A: “Our new patient starts are very, very stable. And they’re very high in both UC and Crohn’s... we have very, very high capture rates. Seventy-five percent overall in IBD in the frontline setting... it’s 80% in Crohn’s, so it’s slightly lower in UC.”
— Jeffrey Stewart, Chief Commercial Officer

Assessment: A granular, evidence-led answer that directly rebuts the most live bear concern on the franchise. A 75–80% frontline capture rate that has held through a direct in-class launch is the strongest available signal of durable physician preference, and the “not a zero-sum game” framing (category expansion plus a head-to-head Entyvio readout coming) is credible. This is the load-bearing wall of the thesis answering its hardest question well.

Pricing Dynamics for SKYRIZI and RINVOQ Into 2026

A recurring line of questioning sought clarity on the pricing trajectory for the two immunology flagships, given the soft Q1 guide. The CFO walked through the 2025 pattern (first-half tailwind, second-half headwind, roughly flat to slightly down on the year) and explained the Q1 2026 Rinvoq comparison.

Q: “Maybe you can just share your thinking around pricing overall on that market... in RINVOQ first day this year and maybe over the next couple of years.”
— Vamil Divan, Guggenheim Securities

A: “You’re going to see low single-digit pricing in ’26 for both products... [for] the first quarter of RINVOQ, you’ll see that pricing headwind, frankly, high single-digit as an unfavorable comparison that RINVOQ is facing on a prior year basis.”
— Scott Reents, Chief Financial Officer

Assessment: This is the mechanical explanation for the soft Q1 guide, and it is benign — a prior-year rebate-timing comparison, not a demand or competitive problem, easing after the first half. It is exactly the kind of detail that should reassure investors who looked at the $2.97–$3.01 Q1 guide in isolation. But the need to explain a below-Street next quarter on a beat-and-guide call is itself a reason the print did not rally.

What They’re NOT Saying

1. They did not foreground the IPR&D basis change: The single most important fact for interpreting the 2026 guide — that it excludes IPR&D while 2025 included it — was stated once, in a single CFO sentence, and never reconciled against the $10.00 base. Management let the optical $10.00 → $14.47 jump stand without volunteering that ~$2.76 of it is a definitional reset. The most generous read is convention; the cynical read is that the cleaner headline flatters the guide.
2. No expected 2026 IPR&D dollar figure: Having excluded IPR&D from the guide, management gave investors no way to estimate what the reported all-in 2026 EPS will actually be — i.e., how far below $14.47 the number lands once real BD charges are booked. With $5B+ of BD in 2025 alone, that omission leaves the headline guide structurally optimistic versus what will print.
3. No hard aesthetics trough date: Q4 toxins grew and the operational decline narrowed to −1.2%, but management guided 2026 aesthetics flat at ~$5.0B and said category growth “will remain challenged.” “Relatively stable share” and a 2027-weighted Trenibot E ramp is not “we expect growth in [period].”
4. No floor on Imbruvica: The asset is guided down again to ~$2.2B in 2026 as IRA pricing compounds CLL erosion, but management offered no terminal-value framing or stabilization path for a still-multi-billion franchise that drags the entire oncology TA negative.
5. The $3.5B Skyrizi royalty was disclosed but not dimensioned: The CFO flagged that 2026 free cash flow “includes roughly $3.5 billion of SKYRIZI royalty payments,” but did not explain the obligation’s duration or trajectory — a material, growing claim on the cash flows of the single most important growth asset.
6. Quiet on the GAAP-to-adjusted bridge: FY2025 GAAP EPS of $2.36 against $10.00 adjusted is an enormous gap, driven by amortization of acquired intangibles plus IPR&D, and management did not frame how investors should weigh the cash-versus-accounting divergence as the BD-heavy strategy continues.

Market Reaction

• Pre-print setup: ABBV closed at $225.66 on February 3, entering the print −1.2% YTD (from $228.49 at 2025 year-end) but +18.8% on a trailing-12-month basis (from $189.95 a year earlier) and +2.5% over the trailing 30 days. The stock sat near the upper end of its $170.16–$244.38 52-week closing range. The S&P 500 entered the day +1.1% YTD, so ABBV had modestly lagged the market into the print — a stock that had drifted up from the ~$218 post-Q3 level to the mid-$220s without making a new high.
• Reaction-day move (BMO print, same session): ABBV gapped down to open $209.78 (−7.0%), traded a wide intraday range of $204.27–$220.85 (−9.5% to −2.1%), and recovered to close at $217.11, −3.8% (−$8.55). Volume of 15.3M ran 2.3x the 6.5M 30-day average. The S&P 500 closed −0.5% on the day, so ABBV underperformed the market by roughly 3.3 points — a clear single-stock sell-off, not a tape effect, though the intraday recovery off the −9.5% low shows real two-way debate.

For the second consecutive print, AbbVie beat and the stock fell — and that pattern is the story. A quarter that beat on revenue and EPS, closed a record year, surpassed the 2027 Skyrizi/Rinvoq target a year early, and guided 2026 above the Street nonetheless dropped 3.8% on 2.3x volume. The proximate causes are specific and rational. First, the 2026 “beat” is partly a definition change — the buyside had effectively already discounted a cleaner ex-IPR&D number, so the optical leap to $14.47 was less than it appeared once harmonized to ~+13% clean growth. Second, the two soft franchises stayed soft: aesthetics guided flat after a −6.1% year, and oncology guided down on Imbruvica IRA pricing. Third, the Q1 guide ($2.97–$3.01) printed below the ~$3.12 Street — a soft near-term set-up management had to explain. And fourth, after the run to ~$228 at the late-2025 peak, the stock carried enough “growth is sustainable” expectation that an asterisked beat could not clear the bar.

The deep intraday gap-down (to −9.5%) and the partial recovery (to −3.8%) capture the debate precisely: the first read was “the EPS jump is mostly accounting and the near-term guide is soft,” and the recovery was the second read — “but the revenue re-acceleration is real, the franchise raise finally came, and ~+13% clean EPS growth at ~15x is not expensive.” That two-way tension is exactly why the setup is tilting toward an upgrade without yet justifying one: the de-rate from $228 plus a visible 2026 re-acceleration is improving the risk/reward, but the print supplied enough blemishes (definition change, flat aesthetics, down oncology, soft Q1) to keep the rating at Hold for one more quarter.

Street Perspective

Debate: Is the 2026 Guide a Real Re-Acceleration or an Accounting Mirage?

Bull view: The 2026 guide implies a genuine inflection — even on the clean ex-IPR&D basis, EPS grows ~13% to ~$14.47, driven by Skyrizi/Rinvoq compounding, ~300bps of operating-margin expansion, and a lower tax rate. After two years of an IPR&D-depressed adjusted line, 2026 finally shows the underlying earnings power the franchise has had all along. The basis change is a cosmetic distraction from a real number.

Bear view: The headline $10.00 → $14.47 jump is engineered — roughly $2.76 of it is a definition change, not growth, and the guide deliberately excludes the BD spend AbbVie will certainly make, so reported 2026 EPS will land below $14.47. A company that changes how it counts in the same breath as it touts a +45% leap is managing optics, and the ~+2% beat of consensus vanishes once you put both years on the same basis.

Our take: The bull has the better of the substance — ~+13% clean EPS growth is real and high-quality, and excluding IPR&D is the more standard convention most peers already use. But the bear’s practical point stands: the guide is an ex-IPR&D ceiling, the reported number will be lower, and the timing of the basis change alongside the headline is unfortunate. This is why we want one clean 2026 print to confirm the ~$14.47 is durable before we re-rate — the number is probably real, but “probably” is what keeps us at Hold for a quarter.

Debate: After Two Straight Negative Prints, Is the De-Rate the Entry Point?

Bull view: ABBV has now fallen on two consecutive beats and sits at ~$217, roughly 15x the 2026 mid — a discount to its own growth profile and below where it traded into Q3. The franchise just surpassed its 2027 target a year early and committed to high-single-digit growth through 2029. Two sell-the-news reactions in a row on good fundamentals is the classic setup for a stock that has fully de-risked and is coiling for a re-rate; you are buying a high-single/low-double-digit compounder on a manufactured dip with a ~3%+ yield.

Bear view: The stock keeps falling on beats because the beats keep carrying asterisks — IPR&D noise, flat aesthetics, down oncology, soft next-quarter guides. ~15x is not cheap for a business whose two laggard franchises are still shrinking and whose flagship EPS guide is flattered by accounting. There is no margin of safety until either aesthetics actually grows or the market sees a clean, all-in EPS print it can trust.

Our take: This is the crux, and the two sides are closer than at Q3. The bull’s setup is genuinely improving — the de-rate from $228 to $217, combined with a visible 2026 re-acceleration and the long-deferred franchise raise, is moving the stock toward our upgrade triggers. But the bear’s point about asterisked beats is why we wait: a third consecutive “good-but-complicated” print argues for confirmation, not anticipation. We are explicitly tilting toward an upgrade — one clean confirming quarter (a Q1 that holds the ~$3.00 line and a 2026 reaffirmation on the new basis) likely gets us there.

Debate: Has Aesthetics Troughed?

Bull view: Q4 was the inflection — Botox Cosmetic returned to growth (+3.8% op.), the operational decline narrowed to −1.2%, and the 2026 guide is flat rather than down. A market-leading, low-penetration, cash-pay category with the Trenibot E funnel-doubler arriving in 2027 is one consumer-confidence tick away from snapping back to a growth contributor AbbVie owns cheaply inside the conglomerate.

Bear view: The full year was down 6.1%, fillers fell double-digits and may be structurally impaired by the “natural look” shift, and management guided 2026 flat while warning category growth “will remain challenged.” Toxin growth in a single seasonal-high quarter is not a trough; this remains a discretionary-consumer business mis-housed in a pharma multiple, capping the consolidated growth rate.

Our take: Genuinely closer to a trough than at Q3 — the Q4 toxin growth is the first real green shoot — but a flat 2026 guide is “stabilized,” not “recovering.” We read it as the strongest evidence yet of a bottoming process without a confirmed bottom. It supports the improving-setup case but is not, on its own, the confirmed aesthetics trough that constitutes one of our explicit upgrade triggers. Like the stock, this pillar is one clean quarter from flipping positive.

Model & Valuation Framework

Valuation framework: At the $217.11 reaction-day close, ABBV trades at approximately 15.0x the 2026 adjusted-EPS guide midpoint of $14.47 (ex-IPR&D). That is a premium to the diversified large-cap pharma peer group (low-teens) that reflects the superior growth profile and the de-risked LOE, but it is a notable de-rate from the ~16x forward the stock carried at the $228 December peak — the multiple has compressed even as the forward base stepped up. On the cleaner like-for-like basis, the stock is growing EPS ~13% and trading at ~15x — a ~1.1x PEG that is reasonable but not cheap, with a ~3%+ dividend yield underpinning the total-return math. The honest caveat: the “15x” uses an ex-IPR&D guide, so the multiple on a reported all-in 2026 number would be modestly higher once real BD charges land.

Fair-value anchor / 12-month framing: We carry our fair-value anchor at roughly ~$215 (base range ~$205–$225), essentially unchanged from Q3 — the de-rate from $228 to $217 has moved the stock toward our anchor rather than moving the anchor. We anchor on ~15–16x the 2026 ex-IPR&D adjusted EPS of ~$14.37–$14.57, which brackets the current price and is supplemented by the ~3%+ yield. A bull case (Q1 holds the line, aesthetics confirms a trough, the multiple holds 16x on a re-rate as the asterisks fade) supports the high-$230s and a retest toward the 52-week high. A bear case (Imbruvica/oncology drags worsen, aesthetics re-accelerates its decline, a 2026 policy print, multiple compresses to ~13x) supports the high-$180s. From $217 the up/down is modestly skewed to the upside now — perhaps +9–12% to the bull versus −12–14% to the bear — which is the quantitative expression of “tilting toward an upgrade.” It is not yet enough asymmetry, with the dividend, to clear the Outperform bar against the S&P 500, but it is closer than it has been at any point in our coverage. We are one confirming quarter from the math flipping.

Thesis Scorecard Post-Earnings

We carry forward the bull and bear pillars established at our August (Q2) initiation and graded at Q3, and re-grade each against the Q4 / FY2025 / initial-2026-guide evidence as of February 5, 2026.

Overall: The business thesis strengthened again — the franchise raise finally arrived (Skyrizi/Rinvoq past the 2027 target a year early), 2026 implies a genuine ~13% clean EPS re-acceleration, the Humira cliff is settled, neuroscience compounds, and the policy overhang was materially bounded by the voluntary government agreement. Two bear pillars moved in opposite directions: valuation is easing (the de-rate improves the setup) and aesthetics is improving toward a trough, but oncology got worse with 2026 guided down. The net is a clearly improving setup that nonetheless still carries enough near-term blemishes — a basis-changed EPS guide, a soft Q1, a flat aesthetics line, a down oncology line — to keep the rating at Hold for one more quarter.

Action: Maintaining Hold — tilting toward an upgrade. Of our three standing upgrade triggers, the long-term Skyrizi/Rinvoq guide raise is now largely satisfied (delivered inside the 2026 guide); the aesthetics trough is closer but not confirmed (Q4 toxin growth, but a flat 2026 guide); and the entry-price trigger has improved (the de-rate to ~$217 from the ~$228 peak). That is real progress on all three — the reason we explicitly flag the setup as improving rather than static. We hold for one more quarter for two reasons: we want the first clean 2026 print to confirm the ~$14.47 ex-IPR&D number is durable earnings power and not partly accounting, and we want to see Q1 hold the ~$3.00 line through the RINVOQ rebate-timing trough. We would upgrade to Outperform on a clean Q1 confirmation, a 2026 reaffirmation, or a confirmed aesthetics return to growth — any of which we view as plausibly one quarter away. We would move to Underperform only on a genuine operational crack the platform cannot earn through — not remotely in evidence today.

Bottom Line: A Better Year, a Real Re-Acceleration, and a Setup Finally Tilting

AbbVie’s Q4 closed the cleanest possible operating year: record revenue of $61.160B, a double beat on the quarter, the Humira cliff turned into a sub-$5B-and-shrinking tail, neuroscience compounding ~20%, and — at last — the long-deferred Skyrizi/Rinvoq long-term raise, delivered by surpassing the 2027 combined target a full year early inside a hard 2026 guide. The 2026 adjusted-EPS guide of $14.37–$14.57 implies a genuine re-acceleration; on a like-for-like ex-IPR&D basis the clean growth is ~13%, high-quality and driven by the right franchises.

And yet, for the second consecutive print, the stock fell — −3.8% to $217.11. That pattern is the investment case in one data point. The market is correctly discounting the part of the optical $10.00 → $14.47 jump that is a definition change rather than growth, the two franchises (aesthetics flat, oncology down) that still drag, and a Q1 guide below the Street. None of those is a fundamental crack — they are the asterisks that keep turning AbbVie’s beats into “good but complicated” prints the tape will not pay up for.

We maintain our Hold rating on AbbVie — but for the first time in our coverage we frame it as a Hold whose setup is tilting toward an upgrade. Each of our three upgrade triggers moved in the right direction this quarter: the long-term guide raise largely arrived, the aesthetics trough got closer, and the de-rate to ~$217 improved the entry. What holds us back one more quarter is the desire to see a single clean confirming print — a Q1 that holds ~$3.00 and a 2026 number the market can trust on the new basis. We are, in the most literal sense, one clean quarter away. We reiterate our three triggers and stay disciplined — for now.